Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

MLA

Honghao Hank Yang, et al. “Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM).” Blood, vol. 136, Nov. 2020, p. 36. EBSCOhost, https://doi.org/10.1182/blood-2020-143005.

APA

Honghao Hank Yang, Robert Vescio, Stephen Lim, James R. Berenson, Tanya M. Spektor, Benjamin Eades, Gary T. Schwartz, Armando Sanchez, Daisy Martinez, Eli Forouzan, Jennifer To, Noemi Silagan, Shahrooz Eshaghian, Ralph V. Boccia, & Regina A. Swift. (2020). Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM). Blood, 136, 36. https://doi.org/10.1182/blood-2020-143005

Chicago

Honghao Hank Yang, Robert Vescio, Stephen Lim, James R. Berenson, Tanya M. Spektor, Benjamin Eades, Gary T. Schwartz, et al. 2020. “Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM).” Blood 136 (November): 36. doi:10.1182/blood-2020-143005.